68ga-a3
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2023 (NCT06194630)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Angiotensin-converting enzyme 2INHIBITOR
ACE2 inhibitor
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06194630 | Early Phase 1 (Phase 1) | Nov 30, 2023 | Chinese Academy of Medical Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1